{"ticker": {"uuid": "92837224-3fae-463b-a680-d1df1341d8c8", "symbol": "AVIR", "name": "Atea Pharmaceuticals\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/atea-pharmaceuticals-begins-phase-1-112845832.html", "source_name": "MT Newswires", "published_at": "2026-07-14T11:28:45+00:00", "published_display": "14 Jul 2026 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus", "summary": "Atea Pharmaceuticals has initiated a Phase 1 clinical trial for AT-587, a potential first-in-class oral antiviral nucleotide analog for Hepatitis E Virus (HEV). This study will assess the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers, aiming to addres", "url": "https://ca.finance.yahoo.com/news/atea-pharmaceuticals-initiates-first-human-110000002.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-14T10:42:32", "published_display": "14 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hepatitis E Has No Approved Treatments as Atea Begins Human Trial", "summary": "Atea Pharmaceuticals (NASDAQ: AVIR) has initiated a Phase 1 clinical trial for AT-587, an oral nucleotide analog aimed at treating hepatitis E virus (HEV), a serious liver disease with no approved treatments. Preclinical studies showed that AT-587 is 30-150 times more potent than", "url": "https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-initiates-first-in-human-phase-1-clinical-trial-gqdfkx1b4tdb.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:42:32", "published_display": "14 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atea Pharmaceuticals (AVIR) Q4 2025 earnings summary", "summary": "Atea Pharmaceuticals reported its Q4 2025 earnings, highlighting an advanced global Phase III HCV program with topline results from C-BEYOND expected in mid-2026 and C-FORWARD by year-end 2026. The company also expanded its antiviral pipeline with an HEV program, expecting first-", "url": "https://quartr.com/events/atea-pharmaceuticals-inc-avir-q4-2025_onnML5Ej", "source_name": "Quartr", "published_at": "2026-07-11T00:40:19", "published_display": "11 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Proxy filing Summary", "summary": "Atea Pharmaceuticals (AVIR) has filed a proxy summary detailing its upcoming annual meeting on June 18, 2026. Key agenda items include the election of three Class III directors, ratification of KPMG LLP as the independent auditor, and an advisory vote on executive compensation. T", "url": "https://quartr.com/events/atea-pharmaceuticals-inc-avir-proxy-filing_onnM3Zni", "source_name": "Quartr", "published_at": "2026-07-11T00:40:19", "published_display": "11 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Q2 2024 earnings summary", "summary": "Atea Pharmaceuticals reported its Q2 2024 earnings, highlighting full enrollment in its Phase 3 SUNRISE-3 COVID-19 and Phase 2 HCV trials, with topline results expected in the second half of 2024. The company's cash position was $502.2 million as of June 30, 2024, projected to fu", "url": "https://quartr.com/events/atea-pharmaceuticals-inc-avir-q2-2024_onnM9QnY", "source_name": "Quartr", "published_at": "2026-07-11T00:40:19", "published_display": "11 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary", "summary": "Atea Pharmaceuticals (AVIR) presented key clinical data from its Phase 2 trials for bemnifosbuvir and ruzasvir in HCV at the 7th Annual Evercore ISI HealthCONx Healthcare Conference. The company reported 98% SVR12 in adherent patients and favorable safety, with plans for an end-o", "url": "https://quartr.com/events/atea-pharmaceuticals-avir-7th-annual-evercore-isi-healthconx-healthcare-conference_onnM9FLT", "source_name": "Quartr", "published_at": "2026-07-10T16:10:52", "published_display": "10 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary", "summary": "Atea Pharmaceuticals reported its Q1 2026 earnings, detailing progress on two pivotal Phase 3 HCV trials (C-BEYOND and C-FORWARD) with topline results expected mid-2026 and year-end 2026, respectively, and a Q1 2027 NDA submission target. The company also expanded its antiviral p", "url": "https://quartr.com/events/atea-pharmaceuticals-inc-avir-q1-2026_onnM3Led", "source_name": "Quartr", "published_at": "2026-07-10T15:39:19", "published_display": "10 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVIR - Atea Pharmaceuticals Inc Short Interest", "summary": "This article provides a detailed financial snapshot of Atea Pharmaceuticals Inc (AVIR), focusing on its short interest, key financial metrics, stock performance, and insider/institutional ownership. It includes information such as market capitalization, income, sales, price-to-bo", "url": "https://finviz.com/stock?t=AVIR&ty=si&p=d", "source_name": "Finviz", "published_at": "2026-07-02T19:41:14", "published_display": "02 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVIR - Atea Pharmaceuticals Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Atea Pharmaceuticals Inc (AVIR), including its stock performance, volatility, key financial ratios, and insider/institutional ownership. It highlights various metrics such as market capitalization, P/E ratio, sales, EPS growt", "url": "https://finviz.com/stock?t=AVIR&ta=1&p=m&ty=ocv&b=2&r=max&ov=list_date&e=2026-10-16", "source_name": "Finviz", "published_at": "2026-07-01T22:39:59", "published_display": "01 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Atea Pharmaceuticals, Inc. \u2013 NASDAQ:AVIR", "summary": "This article provides financial information for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The content offers a brief financial overview within the TradingView platfo", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:39:24", "published_display": "29 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Atea Pharmaceuticals, Inc. \u2013 NASDAQ:AVIR", "summary": "This article focuses on the \"Price to book forward\" metric for Atea Pharmaceuticals, Inc., traded on NASDAQ under the symbol AVIR. It appears to be a financial data page from TradingView, providing an overview of the company's financial information within that platform. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:10:47", "published_display": "28 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. \u2013 BOATS:AVIR", "summary": "This article provides the enterprise value to EBITDA forward for Atea Pharmaceuticals, Inc. (AVIR) as part of the Blue Ocean Alternative Trade System (BOATS) on TradingView. It appears to be a financial data point without further analysis or context on its significance.", "url": "https://www.tradingview.com/symbols/BOATS-AVIR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:24", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. \u2013 NASDAQ:AVIR", "summary": "This article provides a financial snapshot for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its enterprise value to revenue forward. It appears to be a stub or a data point from a larger financial platform, indicating a value change and percentage change for a specific ", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:09:54", "published_display": "28 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Atea Pharmaceuticals, Inc. \u2013 BOATS:AVIR", "summary": "This article displays the \"Price to earnings forward\" information for Atea Pharmaceuticals, Inc. (BOATS:AVIR) on the TradingView platform. It shows the company's ticker symbol, market status, and available financial data sections. The content prominently features the company name", "url": "https://www.tradingview.com/symbols/BOATS-AVIR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:41:11", "published_display": "27 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AVIR)", "summary": "This article provides an overview of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) stock performance, financial estimates, and analyst forecasts. It covers key metrics such as current stock price, market capitalization, historical highs and lows, earnings details, and future revenue ", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:37:49", "published_display": "26 Jun 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVIR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Atea Pharmaceuticals, Inc. (AVIR) stock, including current price, historical performance, analyst price targets, and future earnings estimates. Analysts predict AVIR's price could range from $6.00 to $10.00, with earnings expected on August 6,", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:33", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Completes Enrollment in Phase 3 Hepatitis C Virus Trial Outside North America", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/atea-pharmaceuticals-completes-enrollment-phase-115454005.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:54:54+00:00", "published_display": "25 Jun 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus", "summary": "Atea Pharmaceuticals announced the completion of patient enrollment in its Phase 3 C-FORWARD clinical trial, evaluating bemnifosbuvir and ruzasvir (BEM/RZR) for Hepatitis C virus (HCV) treatment outside North America. The trial enrolled over 880 treatment-na\u00efve patients across 17", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317395/0/en/atea-pharmaceuticals-completes-patient-enrollment-in-phase-3-c-forward-trial-evaluating-bemnifosbuvir-and-ruzasvir-for-treatment-of-hepatitis-c-virus.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T11:11:49", "published_display": "25 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Faces Selling Pressure as Stock Drops 2.58% - Float Adjusted Cap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPY2gwd3BhSEd5YUlBNmJ4YVd5VTFtZGtaU3RQTEJyUVNBVXZvcjBwbG1mdlFuN3dTRzFNdTNYNHltd2lqX3lCalJSYVlCak1aU0VDMzEtTFpzNkNrYml0Y0xlbXlIUGFDTF80bnEzcy13VTJHWnZES3RWWVZCN0hZWmJOYTh1Z3BEQV9Ta0NJS01QempMMW1EdE1EdVVuNHlleE9LdllFc1dvWGVmQWk0bkkzMUVIME1f?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Faces Selling Pressure as Stock Drops 2.58% - Passive Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNQzFMYnlSYXh4WHVVRVpaVmdJMmJ6TDZvTzVLSGExZU5wQnU0MnAxbkFDM1dWNmcxSmtJbXpHOXY5czNXS2RqWVRQNzN3b2JwOThKU0dXRWxCeGtadFZRV2stazk0UjMzNm4yampweFItSjlWMmZwLUt5anI1U3BPLVlPYkFXSUxwY092MEk1ZkxidllPQnJzMklQMTVVc3otZVlFVnBKcmowMkhJelVn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants", "summary": "Atea Pharmaceuticals director Jerome M. Adams exercised 29,600 restricted stock units (RSUs) into common stock and received new grants of 37,700 stock options and 26,700 RSUs. These transactions are described as routine equity compensation, converting previously awarded equity in", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-e1d0d0a02406.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:09:54", "published_display": "24 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) director reports RSU vesting and new option grant", "summary": "Atea Pharmaceuticals director Polly A. Murphy reported equity compensation, including the exercise of 29,600 Restricted Stock Units (RSUs) into common stock, bringing her total direct holdings to 121,745 shares. She also received a new grant of 37,700 stock options with an exerci", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-3633128244db.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:09:54", "published_display": "24 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs", "summary": "Atea Pharmaceuticals director Bruno Lucidi engaged in equity compensation activities, exercising 29,600 restricted stock units into Common Stock, leading to a direct holding of 142,350 Common shares. He also received 37,700 stock options with a $4.36 exercise price and 26,700 new", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-9b3292113114.html", "source_name": "Stock Titan", "published_at": "2026-06-24T08:10:47", "published_display": "24 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVIR SEC Filings - Atea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Atea Pharmaceuticals (AVIR) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights a recent Form 3 filing on June 24, 2025, and summarizes the results of the company's Ju", "url": "https://www.stocktitan.net/sec-filings/AVIR/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-24T08:10:31", "published_display": "24 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com", "summary": "This article reports on a Form 4 filing for Atea Pharmaceuticals Inc. for June 23, 2026. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article notes Atea Pharmaceuticals' stock symbol as AVIR and its recent performanc", "url": "https://ng.investing.com/news/stock-market-news/form-4-atea-pharmaceuticalsinc-for-23-june-93CH-2571027", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T06:40:33", "published_display": "24 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Franklin M. Berger, a director at Atea Pharmaceuticals, Inc. (AVIR), increased his equity exposure through several transactions on June 18, 2026. These included the conversion of 29,600 restricted stock units into common shares, receipt of a stock option for 37,700 shares, and a ", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-2423f5633ae4.html", "source_name": "Stock Titan", "published_at": "2026-06-24T00:41:09", "published_display": "24 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals elects directors and approves proposals at annual meeting", "summary": "Atea Pharmaceuticals (NASDAQ:AVIR) held its 2026 Annual Meeting of Stockholders, electing three Class III directors and approving all proposals, including the ratification of KPMG LLP as the independent public accounting firm and an advisory vote on executive compensation. The co", "url": "https://ng.investing.com/news/stock-market-news/atea-pharmaceuticals-elects-directors-and-approves-proposals-at-annual-meeting-93CH-2569025", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T23:40:09", "published_display": "23 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Howard Berman receives new equity awards at Atea (NASDAQ: AVIR)", "summary": "Atea Pharmaceuticals director Howard Berman was granted new equity awards, including stock options for 37,700 shares at an exercise price of $4.36 and 26,700 restricted stock units. These awards, detailed in a Form 4 SEC filing, are part of his compensation and are subject to ves", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-dd4681f7b934.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:41:09", "published_display": "23 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director", "summary": "Atea Pharmaceuticals director Arthur S. Kirsch has been granted 37,700 stock options with an exercise price of $4.36 per share, vesting monthly between June 2026 and June 2027. He also received 26,700 restricted stock units (RSUs), which will vest in a single installment by June ", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-9b105c493c5a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:41:09", "published_display": "23 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (NASDAQ: AVIR) reports 2026 annual meeting and vote outcomes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQNEtNVzE3RG0tVHRJWHY0R0c3c00xVEJwUFRuLVFUTklQSlRPX2R1TGhrVmxLZmVrbXJyZ1NtcnZha2ZINTk2QVdlZUdjZjhWZHZFZjg1QmFoZzNSTXRfWHp0TTRLbi1yZ3g2SHZYSktqRGNaZW55eThHb3MwZXpWNnp5MGZPTXliZDBPOW12WldLZl9tb1IyREI1Nkw0Rk9EdjJiMmo2UnRhSFctZ2w5Ukt3bw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBMMjF3dW94bEh4czM1enI0VzZqNUpwYkNhc0lTTEpKMUYzMlB3eEVzV1AtTFZaN2lha0hDUFNEQ0pMSW1yQmVSV1I4akF0cHFSOVJfU2lHbVI4alJBQ1BKSThmeTMzMExzZW05d2syb3g5RkRHOWJkQg?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T10:20:33+00:00", "published_display": "18 Jun 2026 10:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQU3dmSk81LTk0RHhsWHI4cnIyNThwT0JjbWRhV2l6ZVFBTGVhRVZFWkZtY2c4cHhrNS1JaEQ4dmxVZy1qazNWVkNUUXg5el9jR0xYTGZCWHZkaFJuOERud01zQUt5MXZwcTJDSW1jZnFDTHF1NzZxc2I1eUE4YnFFODZxS3hRLWc1VEo0bFFObkc2UjE3MEwtbWV0YUpyZlpRVDMzcENR?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging  Atea Pharmaceuticals (AVIR) This Year?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/medical-stocks-lagging-atea-pharmaceuticals-134003759.html", "source_name": "Zacks", "published_at": "2026-06-09T13:40:03+00:00", "published_display": "09 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals - I'm Optimistic Ahead Of Critical HPV Catalyst (NASDAQ:AVIR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNM2d6azNhd3kxVnpDYUMzSWxoUEU5QTdJMlZJSlphNWJlWjZkbTFEdVhpUXBNSWM4VUJpc2VKUUExb2VKelRadVE1YWFyMEYzRU5heG1MYTNCWkRRZW1ieWI5cnc2VWVKeV9ybGlRbDZsWFBZZ3I2Y3FPbDcwMzNucDZ1S0JUSVZFMUVzOUF3YTNqem9oamFMZW1lbFdwQnlkM2RfT1dmbTRSUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/atea-pharmaceuticals-presents-drug-drug-110000902.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNdnA2M0xybFlBT2VLQkpfNkJDS29kTnNVMm9YcU9UT2FhU0dqM1p2MnpjN2tkLVFjaXg5YTZKWUJEQk9iLUlYVlB1WjJPVUszbGMtM1VaWmpXRXZYWWVreDg4WGN5b2Z4czdVS21rT2ItLTU1X1YtV05wLXBPUnpFRndhUEZiVFBYV1lnUGg5eEVGckoySU1rZmlrMDlNNGpSRUFRQ3Jn?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-were-watching-atea-124608109.html", "source_name": "Simply Wall St.", "published_at": "2026-05-19T12:46:08+00:00", "published_display": "19 May 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/down-25-4-weeks-heres-133502172.html", "source_name": "Zacks", "published_at": "2026-05-15T13:35:02+00:00", "published_display": "15 May 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxQTG5saGRCNDV6REVIZC0weGFGY2V2QmxlbGJyMHlraVJKbHNNTGpmdjRTTk9OZUhCdk9uT214WDRvUWlNc0RQbk1qeWpfLUp5Yk1SZGdNNVNmU1VtOHVkZ1liY2VpRTBlTEZrR0tzdERjN1Z6NEVTWXpBaDA1VFBobmNpN3BxcjU1TkhxUGV0WFd5b0RudTB0TEgtV180TWVDUzhZRFI5QVpyZjVzMDNYaTYweGxCUGpYZlZfMjFtM2J4TUJwSDRCcTZGRzlfZF9LT3hFNXNyd2tkd1RZMy1odWR0bXEtanRsMV9FeEdyTXlyTXIzczJfc1R3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOQTZHUmFVdGs0bGJrOGlqc0RhamFuN0pKWUl2U0FDbm1LUHY1Wll1YjNXTGsxWjRNZXlyUDFDcmk1Zm90S0hlc0E0UVF4cWpYbjI0RUJuSlNvMFJSRDRQQVdIOGRKTm1NVzRpY28xejh4YWx4dzdtYnVJUHRTb0dZMnNMTkJTeV81enNqcFRvc1B5V28?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Enjoy US$723k Return After Buying Atea Pharmaceuticals Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-19T07:00:00+00:00", "published_display": "19 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Atea Pharmaceuticals Q4 2024 results weigh on stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPTFhNWWFqRnJZVTlDZzdJWHgweUVWRU0tUE1KVXh0MUVRb1ZLX3RrYWlTUDlsdGkxaERQbnVlaWRPWm1XLUY3VV9mN1YwTkVub29JRHFoT3RmRlEtamRKWFJ2c2RqeHVhWVllN3ZPcGVETVZwWXZFTUZGZXRvYkM4T0hTS2plUFlaVWN3SGZ2a1p1UW0zNzFvVkkxNXlqNnV3aXl5RTNvNXowYTRXR25SMmZISHFlblF4N3RYbjJwbnFScF8xbkp2SmRoZVM?oc=5", "source_name": "Investing.com", "published_at": "2025-03-06T08:00:00+00:00", "published_display": "06 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Short Interest & Short Float | Updated Jul 2026 $AVIR", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5aZVpZZmZSNElVNmNISXUyNWtvekU1dUc5TFUzOHo2TlU4QlhMWDJxZU1GVnJFM21GMXB0WWVaUjRKaXVKamtvUlhqVVpfN1hVTlMwd3cwRFRsZ2J1VnJUSFo5TjF1QXlISjNpNzln?oc=5", "source_name": "MarketBeat", "published_at": "2021-01-31T01:36:58+00:00", "published_display": "31 Jan 2021 01:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis $AVIR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1CTzhmdEpNTjIxMHFZWnk2QzV1U1ZFNC1mQmNmbXAxMVdqYzUtbFpYNlFsN3lZYTdLbW5yc3N1TkpDV25IdFpVX0JQb2o5YnF2dHl2Si15TGxRUQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-18T04:35:13+00:00", "published_display": "18 Aug 2016 04:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/atea-pharmaceuticals-begins-phase-1-112845832.html", "source_name": "MT Newswires", "published_at": "2026-07-14T11:28:45+00:00", "published_display": "14 Jul 2026 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus", "summary": "Atea Pharmaceuticals has initiated a Phase 1 clinical trial for AT-587, a potential first-in-class oral antiviral nucleotide analog for Hepatitis E Virus (HEV). This study will assess the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers, aiming to addres", "url": "https://ca.finance.yahoo.com/news/atea-pharmaceuticals-initiates-first-human-110000002.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-14T10:42:32", "published_display": "14 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hepatitis E Has No Approved Treatments as Atea Begins Human Trial", "summary": "Atea Pharmaceuticals (NASDAQ: AVIR) has initiated a Phase 1 clinical trial for AT-587, an oral nucleotide analog aimed at treating hepatitis E virus (HEV), a serious liver disease with no approved treatments. Preclinical studies showed that AT-587 is 30-150 times more potent than", "url": "https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-initiates-first-in-human-phase-1-clinical-trial-gqdfkx1b4tdb.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:42:32", "published_display": "14 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Q4 2025 earnings summary", "summary": "Atea Pharmaceuticals reported its Q4 2025 earnings, highlighting an advanced global Phase III HCV program with topline results from C-BEYOND expected in mid-2026 and C-FORWARD by year-end 2026. The company also expanded its antiviral pipeline with an HEV program, expecting first-", "url": "https://quartr.com/events/atea-pharmaceuticals-inc-avir-q4-2025_onnML5Ej", "source_name": "Quartr", "published_at": "2026-07-11T00:40:19", "published_display": "11 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Proxy filing Summary", "summary": "Atea Pharmaceuticals (AVIR) has filed a proxy summary detailing its upcoming annual meeting on June 18, 2026. Key agenda items include the election of three Class III directors, ratification of KPMG LLP as the independent auditor, and an advisory vote on executive compensation. T", "url": "https://quartr.com/events/atea-pharmaceuticals-inc-avir-proxy-filing_onnM3Zni", "source_name": "Quartr", "published_at": "2026-07-11T00:40:19", "published_display": "11 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Q2 2024 earnings summary", "summary": "Atea Pharmaceuticals reported its Q2 2024 earnings, highlighting full enrollment in its Phase 3 SUNRISE-3 COVID-19 and Phase 2 HCV trials, with topline results expected in the second half of 2024. The company's cash position was $502.2 million as of June 30, 2024, projected to fu", "url": "https://quartr.com/events/atea-pharmaceuticals-inc-avir-q2-2024_onnM9QnY", "source_name": "Quartr", "published_at": "2026-07-11T00:40:19", "published_display": "11 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary", "summary": "Atea Pharmaceuticals (AVIR) presented key clinical data from its Phase 2 trials for bemnifosbuvir and ruzasvir in HCV at the 7th Annual Evercore ISI HealthCONx Healthcare Conference. The company reported 98% SVR12 in adherent patients and favorable safety, with plans for an end-o", "url": "https://quartr.com/events/atea-pharmaceuticals-avir-7th-annual-evercore-isi-healthconx-healthcare-conference_onnM9FLT", "source_name": "Quartr", "published_at": "2026-07-10T16:10:52", "published_display": "10 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary", "summary": "Atea Pharmaceuticals reported its Q1 2026 earnings, detailing progress on two pivotal Phase 3 HCV trials (C-BEYOND and C-FORWARD) with topline results expected mid-2026 and year-end 2026, respectively, and a Q1 2027 NDA submission target. The company also expanded its antiviral p", "url": "https://quartr.com/events/atea-pharmaceuticals-inc-avir-q1-2026_onnM3Led", "source_name": "Quartr", "published_at": "2026-07-10T15:39:19", "published_display": "10 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVIR - Atea Pharmaceuticals Inc Short Interest", "summary": "This article provides a detailed financial snapshot of Atea Pharmaceuticals Inc (AVIR), focusing on its short interest, key financial metrics, stock performance, and insider/institutional ownership. It includes information such as market capitalization, income, sales, price-to-bo", "url": "https://finviz.com/stock?t=AVIR&ty=si&p=d", "source_name": "Finviz", "published_at": "2026-07-02T19:41:14", "published_display": "02 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVIR - Atea Pharmaceuticals Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Atea Pharmaceuticals Inc (AVIR), including its stock performance, volatility, key financial ratios, and insider/institutional ownership. It highlights various metrics such as market capitalization, P/E ratio, sales, EPS growt", "url": "https://finviz.com/stock?t=AVIR&ta=1&p=m&ty=ocv&b=2&r=max&ov=list_date&e=2026-10-16", "source_name": "Finviz", "published_at": "2026-07-01T22:39:59", "published_display": "01 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Atea Pharmaceuticals, Inc. \u2013 NASDAQ:AVIR", "summary": "This article provides financial information for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The content offers a brief financial overview within the TradingView platfo", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:39:24", "published_display": "29 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Atea Pharmaceuticals, Inc. \u2013 NASDAQ:AVIR", "summary": "This article focuses on the \"Price to book forward\" metric for Atea Pharmaceuticals, Inc., traded on NASDAQ under the symbol AVIR. It appears to be a financial data page from TradingView, providing an overview of the company's financial information within that platform. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:10:47", "published_display": "28 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. \u2013 BOATS:AVIR", "summary": "This article provides the enterprise value to EBITDA forward for Atea Pharmaceuticals, Inc. (AVIR) as part of the Blue Ocean Alternative Trade System (BOATS) on TradingView. It appears to be a financial data point without further analysis or context on its significance.", "url": "https://www.tradingview.com/symbols/BOATS-AVIR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:24", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. \u2013 NASDAQ:AVIR", "summary": "This article provides a financial snapshot for Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), focusing on its enterprise value to revenue forward. It appears to be a stub or a data point from a larger financial platform, indicating a value change and percentage change for a specific ", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:09:54", "published_display": "28 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Atea Pharmaceuticals, Inc. \u2013 BOATS:AVIR", "summary": "This article displays the \"Price to earnings forward\" information for Atea Pharmaceuticals, Inc. (BOATS:AVIR) on the TradingView platform. It shows the company's ticker symbol, market status, and available financial data sections. The content prominently features the company name", "url": "https://www.tradingview.com/symbols/BOATS-AVIR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:41:11", "published_display": "27 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AVIR)", "summary": "This article provides an overview of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) stock performance, financial estimates, and analyst forecasts. It covers key metrics such as current stock price, market capitalization, historical highs and lows, earnings details, and future revenue ", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:37:49", "published_display": "26 Jun 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVIR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Atea Pharmaceuticals, Inc. (AVIR) stock, including current price, historical performance, analyst price targets, and future earnings estimates. Analysts predict AVIR's price could range from $6.00 to $10.00, with earnings expected on August 6,", "url": "https://www.tradingview.com/symbols/NASDAQ-AVIR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:33", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Completes Enrollment in Phase 3 Hepatitis C Virus Trial Outside North America", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/atea-pharmaceuticals-completes-enrollment-phase-115454005.html", "source_name": "MT Newswires", "published_at": "2026-06-25T11:54:54+00:00", "published_display": "25 Jun 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus", "summary": "Atea Pharmaceuticals announced the completion of patient enrollment in its Phase 3 C-FORWARD clinical trial, evaluating bemnifosbuvir and ruzasvir (BEM/RZR) for Hepatitis C virus (HCV) treatment outside North America. The trial enrolled over 880 treatment-na\u00efve patients across 17", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317395/0/en/atea-pharmaceuticals-completes-patient-enrollment-in-phase-3-c-forward-trial-evaluating-bemnifosbuvir-and-ruzasvir-for-treatment-of-hepatitis-c-virus.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T11:11:49", "published_display": "25 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Faces Selling Pressure as Stock Drops 2.58% - Float Adjusted Cap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPY2gwd3BhSEd5YUlBNmJ4YVd5VTFtZGtaU3RQTEJyUVNBVXZvcjBwbG1mdlFuN3dTRzFNdTNYNHltd2lqX3lCalJSYVlCak1aU0VDMzEtTFpzNkNrYml0Y0xlbXlIUGFDTF80bnEzcy13VTJHWnZES3RWWVZCN0hZWmJOYTh1Z3BEQV9Ta0NJS01QempMMW1EdE1EdVVuNHlleE9LdllFc1dvWGVmQWk0bkkzMUVIME1f?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Faces Selling Pressure as Stock Drops 2.58% - Passive Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNQzFMYnlSYXh4WHVVRVpaVmdJMmJ6TDZvTzVLSGExZU5wQnU0MnAxbkFDM1dWNmcxSmtJbXpHOXY5czNXS2RqWVRQNzN3b2JwOThKU0dXRWxCeGtadFZRV2stazk0UjMzNm4yampweFItSjlWMmZwLUt5anI1U3BPLVlPYkFXSUxwY092MEk1ZkxidllPQnJzMklQMTVVc3otZVlFVnBKcmowMkhJelVn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants", "summary": "Atea Pharmaceuticals director Jerome M. Adams exercised 29,600 restricted stock units (RSUs) into common stock and received new grants of 37,700 stock options and 26,700 RSUs. These transactions are described as routine equity compensation, converting previously awarded equity in", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-e1d0d0a02406.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:09:54", "published_display": "24 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) director reports RSU vesting and new option grant", "summary": "Atea Pharmaceuticals director Polly A. Murphy reported equity compensation, including the exercise of 29,600 Restricted Stock Units (RSUs) into common stock, bringing her total direct holdings to 121,745 shares. She also received a new grant of 37,700 stock options with an exerci", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-3633128244db.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:09:54", "published_display": "24 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs", "summary": "Atea Pharmaceuticals director Bruno Lucidi engaged in equity compensation activities, exercising 29,600 restricted stock units into Common Stock, leading to a direct holding of 142,350 Common shares. He also received 37,700 stock options with a $4.36 exercise price and 26,700 new", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-9b3292113114.html", "source_name": "Stock Titan", "published_at": "2026-06-24T08:10:47", "published_display": "24 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AVIR SEC Filings - Atea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Atea Pharmaceuticals (AVIR) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights a recent Form 3 filing on June 24, 2025, and summarizes the results of the company's Ju", "url": "https://www.stocktitan.net/sec-filings/AVIR/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-24T08:10:31", "published_display": "24 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com", "summary": "This article reports on a Form 4 filing for Atea Pharmaceuticals Inc. for June 23, 2026. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article notes Atea Pharmaceuticals' stock symbol as AVIR and its recent performanc", "url": "https://ng.investing.com/news/stock-market-news/form-4-atea-pharmaceuticalsinc-for-23-june-93CH-2571027", "source_name": "Investing.com Nigeria", "published_at": "2026-06-24T06:40:33", "published_display": "24 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Franklin M. Berger, a director at Atea Pharmaceuticals, Inc. (AVIR), increased his equity exposure through several transactions on June 18, 2026. These included the conversion of 29,600 restricted stock units into common shares, receipt of a stock option for 37,700 shares, and a ", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-2423f5633ae4.html", "source_name": "Stock Titan", "published_at": "2026-06-24T00:41:09", "published_display": "24 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals elects directors and approves proposals at annual meeting", "summary": "Atea Pharmaceuticals (NASDAQ:AVIR) held its 2026 Annual Meeting of Stockholders, electing three Class III directors and approving all proposals, including the ratification of KPMG LLP as the independent public accounting firm and an advisory vote on executive compensation. The co", "url": "https://ng.investing.com/news/stock-market-news/atea-pharmaceuticals-elects-directors-and-approves-proposals-at-annual-meeting-93CH-2569025", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T23:40:09", "published_display": "23 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Howard Berman receives new equity awards at Atea (NASDAQ: AVIR)", "summary": "Atea Pharmaceuticals director Howard Berman was granted new equity awards, including stock options for 37,700 shares at an exercise price of $4.36 and 26,700 restricted stock units. These awards, detailed in a Form 4 SEC filing, are part of his compensation and are subject to ves", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-dd4681f7b934.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:41:09", "published_display": "23 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director", "summary": "Atea Pharmaceuticals director Arthur S. Kirsch has been granted 37,700 stock options with an exercise price of $4.36 per share, vesting monthly between June 2026 and June 2027. He also received 26,700 restricted stock units (RSUs), which will vest in a single installment by June ", "url": "https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-9b105c493c5a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:41:09", "published_display": "23 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (NASDAQ: AVIR) reports 2026 annual meeting and vote outcomes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQNEtNVzE3RG0tVHRJWHY0R0c3c00xVEJwUFRuLVFUTklQSlRPX2R1TGhrVmxLZmVrbXJyZ1NtcnZha2ZINTk2QVdlZUdjZjhWZHZFZjg1QmFoZzNSTXRfWHp0TTRLbi1yZ3g2SHZYSktqRGNaZW55eThHb3MwZXpWNnp5MGZPTXliZDBPOW12WldLZl9tb1IyREI1Nkw0Rk9EdjJiMmo2UnRhSFctZ2w5Ukt3bw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBMMjF3dW94bEh4czM1enI0VzZqNUpwYkNhc0lTTEpKMUYzMlB3eEVzV1AtTFZaN2lha0hDUFNEQ0pMSW1yQmVSV1I4akF0cHFSOVJfU2lHbVI4alJBQ1BKSThmeTMzMExzZW05d2syb3g5RkRHOWJkQg?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T10:20:33+00:00", "published_display": "18 Jun 2026 10:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQU3dmSk81LTk0RHhsWHI4cnIyNThwT0JjbWRhV2l6ZVFBTGVhRVZFWkZtY2c4cHhrNS1JaEQ4dmxVZy1qazNWVkNUUXg5el9jR0xYTGZCWHZkaFJuOERud01zQUt5MXZwcTJDSW1jZnFDTHF1NzZxc2I1eUE4YnFFODZxS3hRLWc1VEo0bFFObkc2UjE3MEwtbWV0YUpyZlpRVDMzcENR?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Medical Stocks Lagging  Atea Pharmaceuticals (AVIR) This Year?", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/medical-stocks-lagging-atea-pharmaceuticals-134003759.html", "source_name": "Zacks", "published_at": "2026-06-09T13:40:03+00:00", "published_display": "09 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals - I'm Optimistic Ahead Of Critical HPV Catalyst (NASDAQ:AVIR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNM2d6azNhd3kxVnpDYUMzSWxoUEU5QTdJMlZJSlphNWJlWjZkbTFEdVhpUXBNSWM4VUJpc2VKUUExb2VKelRadVE1YWFyMEYzRU5heG1MYTNCWkRRZW1ieWI5cnc2VWVKeV9ybGlRbDZsWFBZZ3I2Y3FPbDcwMzNucDZ1S0JUSVZFMUVzOUF3YTNqem9oamFMZW1lbFdwQnlkM2RfT1dmbTRSUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/atea-pharmaceuticals-presents-drug-drug-110000902.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNdnA2M0xybFlBT2VLQkpfNkJDS29kTnNVMm9YcU9UT2FhU0dqM1p2MnpjN2tkLVFjaXg5YTZKWUJEQk9iLUlYVlB1WjJPVUszbGMtM1VaWmpXRXZYWWVreDg4WGN5b2Z4czdVS21rT2ItLTU1X1YtV05wLXBPUnpFRndhUEZiVFBYV1lnUGg5eEVGckoySU1rZmlrMDlNNGpSRUFRQ3Jn?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-were-watching-atea-124608109.html", "source_name": "Simply Wall St.", "published_at": "2026-05-19T12:46:08+00:00", "published_display": "19 May 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/down-25-4-weeks-heres-133502172.html", "source_name": "Zacks", "published_at": "2026-05-15T13:35:02+00:00", "published_display": "15 May 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxOb3VqRkxYcnRjSlJlQ2ZRM2FCMnhUS0JWbENYbWlBVWhqNV9tNl9VNUFuNzV0TEp4N1dCUTFNRnJKWmlkcjhxWks0QnhWQVVzejFiSHJsRXpVYlB3M2MweFhIcGFLVE5sUENCSFpGeXBaQjUxUk5uMExxZl84cEUyUkJFWmszUFdMLUhtbGRZbmlENTc4REdKQXBlcDhGcWQ5TGpnb2RWNTQ4SkF3SEpoQ3FXQm5tY243dFJLNXNJbXJ0TFdvSHFnY2JjeDcwcWtBTDJac3BBY1lqZDdwSWh5UTRHREFuUWV6dVHSAe8BQVVfeXFMTTlwV1F3VE5DWE10QmpDUHl4T1AxdjA3SFAteDhZN0Yyb1RuVnpHamFVVUxfQUh6VnVIUUF5NW9UckNHWk8xUEcyc0k0US14TjU2NjY2azd4NEY3MUFHOTNaQk1PVjBBN2VacVRWWnFNRVZvVmVrc0tyNXZOdy1BNng4cW5ra216cWNqZkpadXRYdGUwaUxXeVI2ZHFmUkg3R2xSaEFwSGJoLURTRnh4ek9ONFZOM1BmRVRuZzRaVHV3ZlY3NDhVR25pdlJSUW83NEN3cC1seXc4R0ptWEFiM01QcHVwUFY0aEQzeXJOMjQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxQTG5saGRCNDV6REVIZC0weGFGY2V2QmxlbGJyMHlraVJKbHNNTGpmdjRTTk9OZUhCdk9uT214WDRvUWlNc0RQbk1qeWpfLUp5Yk1SZGdNNVNmU1VtOHVkZ1liY2VpRTBlTEZrR0tzdERjN1Z6NEVTWXpBaDA1VFBobmNpN3BxcjU1TkhxUGV0WFd5b0RudTB0TEgtV180TWVDUzhZRFI5QVpyZjVzMDNYaTYweGxCUGpYZlZfMjFtM2J4TUJwSDRCcTZGRzlfZF9LT3hFNXNyd2tkd1RZMy1odWR0bXEtanRsMV9FeEdyTXlyTXIzczJfc1R3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOQTZHUmFVdGs0bGJrOGlqc0RhamFuN0pKWUl2U0FDbm1LUHY1Wll1YjNXTGsxWjRNZXlyUDFDcmk1Zm90S0hlc0E0UVF4cWpYbjI0RUJuSlNvMFJSRDRQQVdIOGRKTm1NVzRpY28xejh4YWx4dzdtYnVJUHRTb0dZMnNMTkJTeV81enNqcFRvc1B5V28?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Enjoy US$723k Return After Buying Atea Pharmaceuticals Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-19T07:00:00+00:00", "published_display": "19 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Atea Pharmaceuticals Q4 2024 results weigh on stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPTFhNWWFqRnJZVTlDZzdJWHgweUVWRU0tUE1KVXh0MUVRb1ZLX3RrYWlTUDlsdGkxaERQbnVlaWRPWm1XLUY3VV9mN1YwTkVub29JRHFoT3RmRlEtamRKWFJ2c2RqeHVhWVllN3ZPcGVETVZwWXZFTUZGZXRvYkM4T0hTS2plUFlaVWN3SGZ2a1p1UW0zNzFvVkkxNXlqNnV3aXl5RTNvNXowYTRXR25SMmZISHFlblF4N3RYbjJwbnFScF8xbkp2SmRoZVM?oc=5", "source_name": "Investing.com", "published_at": "2025-03-06T08:00:00+00:00", "published_display": "06 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Short Interest & Short Float | Updated Jul 2026 $AVIR", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE5aZVpZZmZSNElVNmNISXUyNWtvekU1dUc5TFUzOHo2TlU4QlhMWDJxZU1GVnJFM21GMXB0WWVaUjRKaXVKamtvUlhqVVpfN1hVTlMwd3cwRFRsZ2J1VnJUSFo5TjF1QXlISjNpNzln?oc=5", "source_name": "MarketBeat", "published_at": "2021-01-31T01:36:58+00:00", "published_display": "31 Jan 2021 01:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis $AVIR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1CTzhmdEpNTjIxMHFZWnk2QzV1U1ZFNC1mQmNmbXAxMVdqYzUtbFpYNlFsN3lZYTdLbW5yc3N1TkpDV25IdFpVX0JQb2o5YnF2dHl2Si15TGxRUQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-18T04:35:13+00:00", "published_display": "18 Aug 2016 04:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 54, "sentiment_summary": {"positive": 10, "negative": 2, "neutral": 42, "score": 53, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 17.55, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 10.45, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 4.99, "latest_week": "2026-07-10", "one_week_move": 0.2, "four_week_move": 11.1, "twelve_week_move": -13.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.614767, "market_dynamics_buy_signal": false, "relative_strength": 5.528921, "fair_value_gap": 38.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.3764, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.2% over one week, +11.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 52, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "Quartr", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.2% over one week, +11.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment"}], "updated_at": "2026-07-16T14:30:35.845674+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}